Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Med Assoc Thai. 2007 Oct;90(10):2158-63.

An open-label study of quetiapine for delirium.

Author information

  • 1Department of Psychiatry, Chiang Mai University, Chiang Mai, Thailand. bkhongsa@mail.med.cmu.ac.th

Abstract

OBJECTIVE:

To evaluate the effects of quetiapine treatment in patients with delirium.

MATERIAL AND METHOD:

All patients with delirium were assessed. The diagnosis of delirium was confirmed by using the Confusion Assessment Method (CAM). Quetiapine at the dose between 25 and 100 mg/day was given for 7 days. The efficacy of quetiapine on delirium was evaluated by using the Delirium Rating Scale (DRS) and the Clinical Global Impression-Severity scale (CGI-S). The extrapyramidal side effects were assessed by using the Modified (9-item) Simpson-Angus Scale (MSAS).

RESULTS:

Twenty-two patients had delirium. Seventeen (10 males and 7 females) subjects with a mean age (SD) of 55.6 (18.6) years were included in the present study. Means (SDs) dose and duration (SD) of quetiapine treatment were 45.7 (28.7) mg/day and 6.5 (2.0) days, respectively. The DRS and CGI-S scores of days 2-7 were significantly lower than those of day 0 (p < 0. 001) for all comparisons). Only two subjects were shown to have mild tremor.

CONCLUSION:

Quetiapine within the range of 25-100 mg/day improves delirious condition within 24 hours of treatment. It is well-tolerated and has a very low propensity to induce extrapyramidal side effects. Further randomized, placebo-controlled trials are warranted.

PMID:
18041437
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk